Perspectives of Cytokine Treatment in Malignant Skin Tumors

  • C. Garbe
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 139)

Abstract

Cytokines have been tested in the treatment of different skin cancers during the last decade, and treatment schedules have been established or proposed for several malignant skin tumors. Preferentially, the interferons and interleukin-2 were found to be effective in treating skin cancers. Interferons alpha and beta have been approved for the treatment of human immunodeficiency virus (HIV)-associated Kaposi’s sarcoma, cutaneous T cell lymphoma, and malignant melanoma in several countries. Interferon alpha was found to be most effective in cutaneous T cell lymphoma with 40%-60% overall responses. When combining interferon alpha with psoralens and ultraviolet A (PUVA) or with retinoids, even higher response rates up to 60%-90% were reported, and long-term remissions have been described. A considerable activity of interferon alpha was found in HIV-associated Kaposi’s sarcoma with response rates of 30%-50%. The effectiveness of Kaposi’s sarcoma’s treatment was further improved by combining interferon alpha and zidovudine. Responses to interferon alpha in metastatic malignant melanoma are rather seldom (10%-15%), but a stabilization of the disease with prolonged survival was reported after interferon alpha treatment. Additionally, interleukin-2 was found to be active in metastatic melanoma, with overall response rates of about 20%, and both biological agents were found to have an additive efficacy in combination. Several combined regimens of interferon alpha, interleukin-2, and polychemotherapy have been described in metastatic melanoma, and overall response rates higher than 50% were found with these combined treatment modalities. Interferon alpha and beta were also intralesionally injected into basal cell carcinomas and other epithelial skin cancers, and complete responses were found in more than 80% of tumors treated. Local applications of interferons and interleukin-2 were likewise found to be effective in the treatment of cutaneous melanoma metastases and cutaneous manifestations of Kaposi’s sarcoma. Cytokines and their combination with other treatment modalities has greatly enriched the treatment facilities in malignant skin tumors during recent years, and additional new cytokines will be introduced in skin cancer treatment in near future.

Keywords

Lymphoma Tamoxifen Neutropenia Retinoid Bleomycin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abrams DI, Volberding PA (1986) Alpha interferon therapy of AIDS-associated Kaposi’s sarcoma. Semin Oncol 13 [3 Suppl 2]:43–47PubMedGoogle Scholar
  2. Altomare GF, Capella GL, Pigatto PD, Finzi AF (1993) Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides. Int J Dermatol 32:138–141PubMedCrossRefGoogle Scholar
  3. Atzpodien J, Körfer A, Franks CR, Poliwoda H, Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-a-2b in advanced human malignancies. Lancet 335:1509–1512PubMedCrossRefGoogle Scholar
  4. Bajetta E, Negretti E, Giannotti B et al (1990) Phase II study of interferon-alpha-2a and dacarbazine in advanced melanoma. Am J Clin Oncol 13:405–409PubMedCrossRefGoogle Scholar
  5. Baumann R, Tauber MG, Opravil M, Hirschel B, Kinloch S, Chave JP, Pletscher M, Luthy R (1991) Combined treatment with zidovudine and lymphoblast interferon-alpha in patients with HIV-related Kaposi’s sarcoma. Klin Wochenschr 69: 360–367PubMedCrossRefGoogle Scholar
  6. Boente P, Sampaio C, Brandao MA, Moreira ED, Badaro R, Jones TC (1993) Local perilesional therapy with rhGM-CSF for Kaposi’s sarcoma (letter). Lancet 341:1154PubMedCrossRefGoogle Scholar
  7. Breier S, Pensei R, Roffe C et al (1990) High dose DTIC with recombinant human interferon alpha-2b (rhifn2b) for the treatment of metastatic malignant melanoma (MMM). Proc Annu Meet Am Soc Clin Oncol 9:A1090Google Scholar
  8. Brockmeyer NH, Mertins L, Daecke C, Goos M (1989) Regression of Kaposi’s sarcoma and improvement of performance status by a combined interferon beta and zidovudine therapy in AIDS patients. J Invest Dermatol 92:776PubMedCrossRefGoogle Scholar
  9. Brunda MJ, Luistro L, Wright RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223–1230PubMedCrossRefGoogle Scholar
  10. Brysk MM, Santschi CH, Bell T, Wagner RF Jr, Tyring SK, Rajaraman S (1992) Culture of basal cell carcinoma. J Invest Dermatol 98:45–49PubMedCrossRefGoogle Scholar
  11. Buechner SA (1991) Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression. J Am Acad Dermatol 24:731–734PubMedCrossRefGoogle Scholar
  12. Bunn PA Jr, Foon KA, Ihde DC, Longo DL, Eddy J, Winkler CF, Veach SR, Zeffren J, Sherwin S, Oldham R (1984) Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 101: 484–487PubMedGoogle Scholar
  13. Bunn PA Jr, Ihde DC, Foon KA (1986) The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 57:1689–1695PubMedCrossRefGoogle Scholar
  14. Castello G, Cornelia P, Manzo T, Napolitano M, Parziale AP, Galati MG, Daponte A, Casaretti R, Celentano E, Cornelia G (1993) Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma. Melanoma Res 3:43–49PubMedCrossRefGoogle Scholar
  15. Celerier P, Fleischmann M, Basset Seguin N, Thill L, Bureau B, Litoux P, Dreno B (1993) In vitro induction of basal keratinocyte MY7 antigen expression in cutaneous T-cell lymphoma is associated with response to interferon-alfa therapy. Arch Dermatol 129:1136–1140PubMedCrossRefGoogle Scholar
  16. Cornell RC, Greenway HY, Tucker SB, Edwards L, Ashworth S, Vance JC, Tanner DJ, Taylor EL, Smiles KA, Peets EA (1990) Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 23:694–700PubMedCrossRefGoogle Scholar
  17. Crowley NJ, Seigier HF (1993) Possibilities of immunotherapy and gene therapy for malignant melanoma. Semin Surg Oncol 9:273–278PubMedGoogle Scholar
  18. Davey RT Jr, Davey VJ, Metcalf JA, Zurlo JJ, Kovacs JA, Falloon J, Polis MA, Zunich KM, Masur H, Lane HC (1991) A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 164: 43–52PubMedCrossRefGoogle Scholar
  19. Demchak PA, Mier JW, Robert NJ et al (1990) Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 9:1821–1830Google Scholar
  20. Dillman RO, Oldham RK, Barth NM et al (1990) Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst 82:1345–1349PubMedCrossRefGoogle Scholar
  21. Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R (1993) Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 71:2358–2370PubMedCrossRefGoogle Scholar
  22. Dreno B, Fleischmann M, Valard S, Godefroy W, Bureau B, Stadler JF, Litoux P (1992) Induction of myelo-monocytic My7 antigen (CD13) expression by interferon-alpha in basal cells of cutaneous T-cell lymphomas. Br J Dermatol 126:320–323PubMedCrossRefGoogle Scholar
  23. Dreno B, Celerier P, Litoux P (1993) Roferon-A in combination with Tigason in cutaneous T-cell lymphomas. Acta Haematol 89 [Suppl l]:28–32PubMedCrossRefGoogle Scholar
  24. Dummer R, Muller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Bill E, Burg G (1991) Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-rish malignant melanoma patients. Cancer 67:2300–2304PubMedCrossRefGoogle Scholar
  25. Edwards L, Tucker SB, Perednia D, Smiles KA, Taylor EL, Tanner DJ, Peets E (1990) The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas. Arch Dermatol 126:1029–1032PubMedCrossRefGoogle Scholar
  26. Elsässer Beile U, Garbe C, Stadler R, Drews H, Schöpf E (1989) Adjuvante Therapie mit rekombiniertem Interferon alfa-2a beim metastasierten malignen Melanom. Hautarzt 40:266–270PubMedGoogle Scholar
  27. Falkson CI, Falkson G, Falkson HC (1991) Improved results with the addition of recombinant interferon alpha-2b to dacarbazine in treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403–1408PubMedGoogle Scholar
  28. Fierlbeck G, d’Hoedt B, Stroebel W, Stutte H, Bogenschütz O, Rassner G (1992) Intraläsionale Therapie von Melanommetastasen mit rekombinantem Interferonbeta. Hautarzt 43:16–21PubMedGoogle Scholar
  29. Fischl MA (1991) Antiretroviral therapy in combination with interferon for AIDS-related Kaposi’s sarcoma. Am J Med 90:2S–7SPubMedCrossRefGoogle Scholar
  30. Fischl M, Lucas S, Gorowski E et al (1986) Interferon alpha-N1 Wellferon (WFN) in Kaposi’s sarcoma: single agent or combination with vinblastine (VBL). J Interferon Res 6 [Suppl 1]:4 (abstr)Google Scholar
  31. Fischl MA, Uttamchandani RB, Resnick L, Agarwal R, Fletcher MA, Patrone Reese J, Dearmas L, Chidekel J, McCann M, Myers M (1991) A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi’s sarcoma. J Acquir Immune Defic Syndr 4:1–10PubMedGoogle Scholar
  32. Flaherty LE, Redman BG, Chabot GG et al (1990) A phase I–II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 65:2471–2477PubMedCrossRefGoogle Scholar
  33. Foon KA, Roth MS, Bunn PA Jr (1987) Interferon therapy of non-Hodgkin’s lymphoma. Cancer 59 [3 Suppl]:601–604PubMedCrossRefGoogle Scholar
  34. Ganser A, Brucher W, Brodt HR, Busch W, Brandhorst I, Helm EB, Hoelzer D (1986) Treatment of AIDS-related Kaposi’s sarcoma with recombinant gamma-interferon. Onkologie 9:163–166PubMedCrossRefGoogle Scholar
  35. Garbe C, Krasagakis K (1993) Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 100:239S–244SPubMedCrossRefGoogle Scholar
  36. Garbe C, Krasagakis K, Zouboulis C, Schröder K, Krüger S, Stadler R, Orfanos CE (1990) Antitumor activities of interferon-alpha, -beta and -gamma on malignant melanoma cells in vitro. Changes of proliferation, melanin synthesis and immuno-phenotype. J Invest Dermatol 95:231S–237SPubMedCrossRefGoogle Scholar
  37. Garbe C, Kreuser ED, Zouboulis CC, Stadler R, Orfanos CE (1992) Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. Semin Oncol 19 [Suppl 4]:63–69PubMedGoogle Scholar
  38. Garbe C, Zouboulis ChC, Stadler R et al (1994) Prolongation of life in stage IV melanoma by combined treatment with IFN-a-2a and vindesine (submitted for publication)Google Scholar
  39. Gelmann EP, Preble OT, Steis R, Lane HC, Rook AH, Wesley M, Jacob J, Fauci A, Masur H, Longo D (1985) Human lymphoblastoid interferon treatment of Kaposi’s sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters. Am J Med 78:737–741PubMedCrossRefGoogle Scholar
  40. Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C (1986) Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 15:437–443PubMedCrossRefGoogle Scholar
  41. Grob JJ, Collet AM, Munoz MH, Bonerandi JJ (1988) Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a. Lancet 1:878–879PubMedCrossRefGoogle Scholar
  42. Groopman JE, Gottlieb MS, Goodman J, Mitsuyasu RT, Conant MA, Prince H, Fahey JL, Derezin M, Weinstein WM, Casavante C et al (1984) Recombinant alpha-2 interferon herapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 100:671–676PubMedGoogle Scholar
  43. Gundersen S, Flokkmann A (1989) Interferon in combination with vinblastine in advanced malignant melanoma. A phase I–II study. Cancer 64:1617–1619PubMedCrossRefGoogle Scholar
  44. Hamblin TJ, Davies B, Sadullah S, Oskam R, Palmer P, Franks CR (1991) A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cisplatin, interleukin-2 (IL-2) and alfa-interferon (IFN). Proc Annu Meet Am Soc Clin Oncol 10:A1029Google Scholar
  45. Hauschild A, Petres Dunsche C (1992) Intraläsionäre Behandlung des klassischen Kaposi-Sarkoms mit Interferon alpha. Hautarzt 43:789–791PubMedGoogle Scholar
  46. Heagy W, Groopman J, Schindler J, Finberg R (1990) Use of IFN-gamma in patients with AIDS. J Acquir Immune Defic Syndr 3:584–590PubMedGoogle Scholar
  47. Hersey P, McLeod RC, Thomson DB (1989) Phase I/II study of tolerability and efficacy of recombinant interferon (Roferon) with dacarbazine (DTIC) in advanced malignant melanoma. J Interferon Res 9 [Suppl 2]: 118Google Scholar
  48. Hill AD, Redmond HP, Croke DT, Grace PA, Bouchier Hayes D (1992) Cytokines in tumour therapy. Br J Surg 79:990–997PubMedCrossRefGoogle Scholar
  49. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW (1992) Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 84:1185–1190PubMedCrossRefGoogle Scholar
  50. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, Richter M, Brado B, Mitrou PS, Hunstein W (1993) Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 72:607–614PubMedCrossRefGoogle Scholar
  51. Kellokumpu-Lehtinen P, Nordman E, Toivanen A (1989) Combined interferon and vinblastine treatment of advanced melanoma: evaluation of the treatment results and the effects of treatment on immunological functions. Cancer Immunol Immunother 28:213–217PubMedCrossRefGoogle Scholar
  52. Kern P, Meigel W, Racz P, Gottesleben A, Dettke T, Dietrich M (1987) Interferon alpha in the treatment of AIDS-associated Kaposi’s sarcoma. Onkologie 10:50–52PubMedCrossRefGoogle Scholar
  53. Kerr R, Pippen P, Mennel R, Jones S (1989) Treatment of metastatic malignant melanoma with a combination of interferon-alpha-2a (IFN-alpha-2a, Roferon) and dacarbazine (DTIC). Proc Annu Meet Am Soc Clin Oncol 8:A1122Google Scholar
  54. Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Phelps R, Franco S, Longo DL, Bunn PA, Ihde DC (1990) Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome. J Clin Oncol 8:155–160PubMedGoogle Scholar
  55. Kovacs JA, Deyton L, Davey R, Falloon J, Zunich K, Lee D, Metcalf JA, Bigley JW, Sawyer LA, Zoon KC et al (1989) Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 111:280–287PubMedGoogle Scholar
  56. Krasagakis K, Garbe C, Kruger S, Orfanos CE (1991) Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. J Invest Dermatol 97:364–372PubMedCrossRefGoogle Scholar
  57. Krigel RL, Odajnyk CM, Laubenstein LJ, Ostreicher R, Wernz J, Vilcek J, Pubinstein P, Friedman Kien AE (1985) Therapeutic trial of interferon-gamma in patients with epidemic Kaposi’s sarcoma. J Biol Response Mod 4:358–364PubMedGoogle Scholar
  58. Krigel RL, Padavic Shaller KA, Rudolph AR, Poiesz BJ, Comis RL (1989) Exacerbation of epidemic Kaposi’s sarcoma with a combination of interleukin-2 and beta-interferon: results of a phase 2 study. J Biol Response Mod 8:359–365PubMedGoogle Scholar
  59. Krown SE, Real FX, Cunningham Rundles S, Myskowski PL, Koziner B, Fein S, Mittelman A, Oettgen HF, Safai B (1983) Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma. N Engl J Med 308:1071–1076PubMedCrossRefGoogle Scholar
  60. Krown SE, Real FX, Vadhan Raj S, Cunningham Rundles S, Krim M, Wong G, Oettgen HF (1986) Kaposi’s sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer 57 [8 Suppl]: 1662–1665PubMedCrossRefGoogle Scholar
  61. Krown SE, Gold JW, Niedzwiecki D, Bundow D, Flomenberg N, Gansbacher B, Brew BJ (1990) Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologie effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 112:812–821PubMedGoogle Scholar
  62. Kuzel TM, Gilyon K, Springer E, Variakojis D, Kaul K, Bunn PA Jr, Evans L, Roenigk HH Jr, Rosen ST (1990) Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82:203–207PubMedCrossRefGoogle Scholar
  63. Kuzel TM, Roenigk HH Jr, Samuelson E, Rosen ST (1992) Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion. J Natl Cancer Inst 84:119–121PubMedCrossRefGoogle Scholar
  64. Landthaler M, Braun Falco O (1989) Adjuvant therapy of high-risk malignant melanoma patients with gamma interferon. J Am Acad Dermatol 20:687–688PubMedCrossRefGoogle Scholar
  65. Lane HC, Davey RT Jr, Sherwin SA, Masur H, Rook AH, Manischewitz JF, Quinnan GV, Smith PD, Easter ME, Fauci AS (1989) A phase I trial of recombinant human interferon-gamma in patients with Kaposi’s sarcoma and the acquired immunodeficiency syndrome (AIDS). J Clin Immunol 9:351–361PubMedCrossRefGoogle Scholar
  66. Legha S, Plager C, Ring S, Eton O, Talpaz J, Gutterman J, Benjamin RS (1992) A phase II study of biochemotherapy using interleukin-2 (IL-2) + Interferon alfa-2a (IFN) in combination with cisplatin (C) vinblastine (V) and DTIC (D) in patients with metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 11:A1179Google Scholar
  67. Lollini PL, De Giovanni C, Nicoletti G, Bontadini A, Tazzari PL, Landuzzi L, Scotlandi K, Nanni P (1990) Enhancement of experimental metastatic ability by tumor necrosis factor-alpha alone or in combination with interferon-gamma. Clin Exp Metastasis 8:215–224PubMedCrossRefGoogle Scholar
  68. Lutzner MA, Blanchet Bardon C, Orth G (1984) Clinical observations, virologic studies, and treatment trials in patients with epidermodysplasia verruciformis, a disease induced by specific human papillomaviruses. J Invest Dermatol 83: 18S-25SPubMedCrossRefGoogle Scholar
  69. Margolin K, Doroshow J, Akman S et al (1990) Treatment (RX) of advanced melanoma with cis-diamminedichloroplatinum (CDDP) and alpha interferon (alpha IFN). Proc Annu Meet Am Soc Clin Oncol 9:A1074Google Scholar
  70. Meyskens FL Jr, Kopecky K, Samson M, Hersh E, Macdonald J, Jaffe H, Crowley J, Coliman C (1990) Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma. J Natl Cancer Inst 82:1071PubMedGoogle Scholar
  71. Miles SA, Wang HJ, Cortes E, Carden J, Marcus S, Mitsuyasu RT (1990) Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections. Ann Intern Med 112:582–589PubMedGoogle Scholar
  72. Mostow EN, Neckel SL, Oberhelman L, Anderson TF, Cooper KD (1993) Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 129:747–752PubMedCrossRefGoogle Scholar
  73. Mozzanica N, Cattaneo A, Boneschi V, Brambilla L, Melotti E, Finzi AF (1990) Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha 2-interferon. Arch Dermatol Res 282:311–317PubMedCrossRefGoogle Scholar
  74. Mulder NH, Schraffordt-Koops H, Sleijfer DT et al (1990) Dacarbazine and alpha-interferon for disseminated malignant melanoma. Proc Annu Meet Am Soc Clin Oncol 9:A1083Google Scholar
  75. Nicolas JF, Balblanc JC, Frappaz A, Chouvet B, Delcombel M, Thivolet J (1989) Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a. Dermatologica 179:34–37PubMedCrossRefGoogle Scholar
  76. Ogasawara M, Rosenberg SA (1993) Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes. Cancer Res 53: 3561–3568PubMedGoogle Scholar
  77. Olsen EA, Rosen ST, Vollmer RT, Variakojis D, Roenigk HH Jr, Diab N, Zeffren J (1989) Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 20:395–407PubMedCrossRefGoogle Scholar
  78. Oratz R, Dugan M, Walsh C et al (1989) Phase II trial of r-alpha 2b-interferon (IFN) and cisplatin (CDDP) in metastatic malignant melanoma (MM). Proc Annu Meet Am Soc Clin Oncol 8:A1123Google Scholar
  79. Otte HG, Herges A, Stadler R (1992) Kombinationstherapie mit Interferon alfa 2a und PUVA bei kutanen T-Zell-Lymphomen. Hautarzt 43:695–699PubMedGoogle Scholar
  80. Plettenberg A, Kern P, Dietrich M, Meigel W (1990) Rekombinantes Interferon alpha 2A in der Behandlung des HIV-assoziierten Kaposi-Sarkoms. Langzeitergebnisse. Med Klin 85:647–652Google Scholar
  81. Pyrhonen S, Hahka Kemppinen M, Muhonen T (1992a) A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 10: 1919–1926PubMedGoogle Scholar
  82. Pyrhonen S, Kouri M, Holsti LR, Cantell K (1992b) Disease stabilization by leukocyte alpha interferon and survival of patients with metastatic melanoma. Oncology 49:22–26PubMedGoogle Scholar
  83. Real FX, Oettgen HF, Krown SE (1986) Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 4:544–551PubMedGoogle Scholar
  84. Richards J, Mehta N, Schroeder L, Dordal A (1992a) Sequential chemotherapy/immunotherapy for metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 11:A1189Google Scholar
  85. Richards JM, Mehta N, Ramming K, Skosey P (1992b) Sequential chemoimmuno-therapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338–1343PubMedGoogle Scholar
  86. Richner J, Cerny T, Joss RA et al (1990) A phase II study of continuous sc alpha-2b interferon (IFN) combined with cisplatin (CDDP) in advanced malignant melanoma (MM). Proc Annu Meet Am Soc Clin Oncol 9:A1085Google Scholar
  87. Rios A, Mansell PW, Newell GR, Reuben JM, Hersh EM, Gutterman JU (1985) Treatment of acquired immunodeficiency syndrome-related Kaposi’s sarcoma with lymphoblastoid interferon. J Clin Oncol 3:506–512PubMedGoogle Scholar
  88. Roenigk HH Jr, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PA Jr et al (1990) Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95 [Suppl 6]:198S–205SPubMedCrossRefGoogle Scholar
  89. Ron IG, Inbar MJ, Gutman M, Merimsky O, Chaitchik S (1993) Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients. Cancer Immunol Immunother 37:61–66PubMedCrossRefGoogle Scholar
  90. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492PubMedCrossRefGoogle Scholar
  91. Rosenberg SA (1992) Gene therapy for cancer. JAMA 268:2416–2419PubMedCrossRefGoogle Scholar
  92. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989a) Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474–485PubMedCrossRefGoogle Scholar
  93. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE (1989b) Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863–1874PubMedGoogle Scholar
  94. Ross C, Tingsgaard P, Jorgensen H, Vejlsgaard GL (1993) Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 51:63–72PubMedCrossRefGoogle Scholar
  95. Rozenbaum W, Gharakhanian S, Navarette MS, De Sahb R, Cardon B, Rouzioux C (1990) Long-term follow-up of 120 patients with AIDS-related Kaposi’s sarcoma treated with interferon alpha-2a. J Invest Dermatol 95 [Suppl 6]:161S–165SPubMedCrossRefGoogle Scholar
  96. Sawyer LA, Metcalf JA, Zoon KC, Boone EJ, Kovacs JA, Lane HC, Quinnan GV Jr (1990) Effects of interferon-alpha in patients with AIDS-associated Kaposi’s sarcoma are related to blood interferon levels and dosse. Cytokine 2:247–252PubMedCrossRefGoogle Scholar
  97. Scadden DT, Bering HA, Levine JD, Bresnahan J, Evans L, Epstein C, Groopman JE (1991a) GM-CSF as an alternative to dose modification of the combination zidovudine and interferon-alpha in the treatment of AIDS-associated Kaposi’s sarcoma. Am J Clin Oncol 14 [Suppl l]:S40–44PubMedCrossRefGoogle Scholar
  98. Scadden DT, Bering HA, Levine JD, Bresnahan J, Evans L, Epstein C, Groopman JE (1991b) Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi’s sarcoma. J Clin Oncol 9:802–808PubMedGoogle Scholar
  99. Schaart FM, Bratzke B, Ruszczak Z, Stadler R, Ehlers G, Orfanos CE (1991) Long-term therapy of HIV-associated Kaposi’s sarcoma with recombinant interferon alpha-2a. Br J Dermatol 124:62–68PubMedCrossRefGoogle Scholar
  100. Schröder K, Garbe C, Waibel M, Reupke H, Detmar M, Dallenbach F, Orfanos CE (1992) Granulozyten-Koloniestimulierender Faktor (G-CSF) in der Behandlung von Patienten mit HIV-assoziiertem mukokutanem Kaposi-Sarkom. Erfolgreicher Einsatz bei virus- bzw. medikamenteninduzierter Leukopenie. Hautarzt 43: 700–706PubMedGoogle Scholar
  101. Schuchter L, McGuire WP, Wohlganger J, Redden T (1989) Sequential treatment of metastatic melanoma with interferon-alpha (IFN) plus cis-platinum (CDDP). Proc Annu Meet Am Soc Clin Oncol 8:A1120Google Scholar
  102. Sertoli MR, Queirolo P, Bajetta E et al (1992) Dacarbazine (DTIC) with or without recombinant interferon alpha-2a at different dosages in the treatment of stage IV melanoma patients. Preliminary results of a randomized trial. Proc Annu Meet Am Soc Clin Oncol 11:A1185Google Scholar
  103. Simoni R, Cavalieri R, Coppola G, Ricciotti L, De Pita O, Criscuolo D, Covelli A, Papa G, Mandelli F (1987) Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides. J Biol Regul Homeost Agents 1:93–99PubMedGoogle Scholar
  104. Smith KA, Green JA, Eccles JM (1992) Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma. Eur J Cancer 28:438–441PubMedCrossRefGoogle Scholar
  105. Springer EA, Kuzel TM, Variakojis D, Kaul K, Rosen ST, Roenigk HH Jr (1993) Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a. J Am Acad Dermatol 29:42–46PubMedCrossRefGoogle Scholar
  106. Stadler R, Garbe C (1991) Disseminated malignant melanoma. New therapeutic approaches. Int J Dermatol 30:239–242PubMedCrossRefGoogle Scholar
  107. Stadler R, Bratzke B, Schaart F, Orfanos CE (1990) Long-term combined rIFN-alpha-2a and zidovudine therapy for HIV-associated Kaposi’s sarcoma: clinical consequences and side effects. J Invest Dermatol 95 [Suppl 6]:170S–175SPubMedCrossRefGoogle Scholar
  108. Tank B, Habets JM, Naafs B, Damsma O, Stolz E, van Joost T (1989) Intralesional treatment of basal cell carcinoma with low-dose recombinant interferon gamma. J Am Acad Dermatol 21:734–735PubMedCrossRefGoogle Scholar
  109. Thestrup Pedersen K, Hammer R, Kaltoft K, Sogaard H, Zachariae H (1988) Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate. Br J Dermatol 118:811–818PubMedCrossRefGoogle Scholar
  110. Thomson D, Adena M, McLeod GRC et al (1992) Interferon-2a (IFN) does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma: results of a multi-institutional Australian randomized trial QMP8704. Proc Annu Meet Am Soc Clin Oncol 11:A1177Google Scholar
  111. Tura S, Mazza P, Zinzani PL, Ghetti PL, Poletti G, Gherlinzoni F, Montagnani A, Criscuolo D (1987) Alpha recombinant interferon in the treatment of mycosis fungoides (MF). Haematologica 72:337–340PubMedGoogle Scholar
  112. Vegna ML, Papa G, Defazio D, Pisani F, Coppola G, De Pita O, Puddu P, Ferranti G, Simoni R, Mandelli F (1990) Interferon alpha-2a in cutaneous T-cell lymphoma. Eur J Haematol Suppl 52:32–35PubMedGoogle Scholar
  113. Volberding P, Valero R, Rothman J, Gee G (1984) Alpha interferon therapy of Kaposi’s sarcoma in AIDS. Ann NY Acad Svi 437:439–446CrossRefGoogle Scholar
  114. Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ (1987) Treatment of Kaposi’s sarcoma with interferon alfa-2b (Intron A). Cancer 59 [Suppl 3]:620–625PubMedCrossRefGoogle Scholar
  115. Von Wussow P, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61:1071–1074CrossRefGoogle Scholar
  116. Wadler S (1992) The role of interferons in the treatment of solid tumors. Cancer 70 [Suppl 4]:949–958PubMedGoogle Scholar
  117. Whitehead RP, Figlin R, Citron ML, Pfile J, Moldawer N, Patel D, Jones G, Levitt D, Zeffren J (1993) A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma. J Immuno-ther 13:117–121CrossRefGoogle Scholar
  118. Wickramasinghe L, Hindson TC, Wacks H (1989) Treatment of neoplastic skin lesions with intralesional interferon. J Am Acad Dermatol 20:71–74PubMedCrossRefGoogle Scholar
  119. Zachariae H, Thestrup Pedersen K (1990) Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95 [Suppl 6]:206S–208SPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1995

Authors and Affiliations

  • C. Garbe
    • 1
  1. 1.University Department of Dermatology, Medical Center SteglitzThe Free University of BerlinBerlinGermany

Personalised recommendations